Insider Buying: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Purchases $15,172,500.00 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) major shareholder Group Walters purchased 4,335,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Zentalis Pharmaceuticals Stock Down 0.3%

Shares of ZNTL stock opened at $3.83 on Friday. The company has a 50 day moving average price of $4.35 and a 200-day moving average price of $3.67. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.21 and a 52 week high of $6.95. The firm has a market capitalization of $274.50 million, a PE ratio of -1.96 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. Sivia Capital Partners LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $27,000. CTC Alternative Strategies Ltd. purchased a new stake in Zentalis Pharmaceuticals in the first quarter worth about $29,000. Qube Research & Technologies Ltd purchased a new stake in Zentalis Pharmaceuticals in the second quarter worth about $37,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $41,000. Finally, State of Wyoming bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $67,000.

Wall Street Analyst Weigh In

ZNTL has been the subject of several research analyst reports. Mizuho started coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $6.75.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.